Lupin patent expiration

1. Antara (micronized) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863331 LUPIN Pharmaceutical composition containing fenofibrate and method for the preparation thereof
Aug, 2020

(3 years ago)

US7101574 LUPIN Pharmaceutical composition containing fenofibrate and the preparation method
Aug, 2020

(3 years ago)

US8026281 LUPIN Treating metabolic syndrome with fenofibrate
Apr, 2025

(9 months from now)

US9314447 LUPIN Reduced dose pharmaceutical compositions of fenofibrate
May, 2033

(8 years from now)




Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 18 October, 2013

Treatment: Treating hypercholesterolemias with reduction of food effect; Treating severe hypertriglyceridemia

Dosage: CAPSULE

How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage

ANTARA (MICRONIZED) family patents

Family Patents

2. Brovana patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6589508 LUPIN Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
Apr, 2013

(11 years ago)

US6040344 LUPIN Formoterol process
Nov, 2016

(7 years ago)

US7462645 LUPIN Bronchodilating beta-agonist compositions and methods
Jun, 2021

(3 years ago)

US7473710 LUPIN Bronchodilating beta-agonist compositions and methods
Jun, 2021

(3 years ago)

US7541385 LUPIN Bronchodilating β-agonist compositions and methods
Jun, 2021

(3 years ago)

US7348362 LUPIN Bronchodilating β-agonist compositions and methods
Jun, 2021

(3 years ago)

US6814953 LUPIN Bronchodilating compositions and methods
Jun, 2021

(3 years ago)

US6667344 LUPIN Bronchodilating compositions and methods
Jun, 2021

(3 years ago)

US7465756 LUPIN Bronchodilating beta-agonist compositions and methods
Jun, 2021

(3 years ago)

US6472563 LUPIN Formoterol tartrate process and polymorph
Nov, 2021

(2 years ago)

US8110706 LUPIN Formoterol tartrate process and polymorph
Nov, 2021

(2 years ago)

US6720453 LUPIN Formoterol tartrate polymorph
Nov, 2021

(2 years ago)

US7145036 LUPIN Formoterol tartrate polymorph
Nov, 2021

(2 years ago)




Drugs and Companies using ARFORMOTEROL TARTRATE ingredient

Market Authorisation Date: 06 October, 2006

Treatment: For the long term treatment, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis ...

Dosage: SOLUTION

How can I launch a generic of BROVANA before it's drug patent expiration?
More Information on Dosage

BROVANA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Sesquient patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US8410077 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US7635773 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9200088 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9493582 LUPIN Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)




Drugs and Companies using FOSPHENYTOIN SODIUM ingredient

Market Authorisation Date: 05 November, 2020

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

SESQUIENT family patents

Family Patents

4. Solosec patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849884 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US10682338 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11000508 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(11 years from now)

US11000507 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11020377 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11324721 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(11 years from now)

US10335390 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11602522 LUPIN Secnidazole for use in the treatment of sexually transmitted infection
Sep, 2035

(11 years from now)

US10857133 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11684607 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2022
New Indication(I-866) Jun 30, 2024
New Patient Population(NPP) Jan 26, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 15, 2027

Drugs and Companies using SECNIDAZOLE ingredient

NCE-1 date: 15 September, 2026

Market Authorisation Date: 15 September, 2017

Treatment: Treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in female patients 12 years of age and older

Dosage: GRANULE

More Information on Dosage

SOLOSEC family patents

Family Patents

5. Xopenex Hfa patent expiration

XOPENEX HFA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7256310 LUPIN Levalbuterol salt
Oct, 2024

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5362755 LUPIN Method for treating asthma using optically pure (R)-albuterol
Mar, 2013

(11 years ago)

US5547994 LUPIN Method for treating asthma using optically pure R(-) albuterol
Aug, 2013

(10 years ago)

US5605674 LUPIN Medicinal aerosol formulations
Feb, 2014

(10 years ago)

US5836299 LUPIN Seals for use in an aerosol delivery device
Nov, 2015

(8 years ago)

US8765153 LUPIN Levalbuterol salt
Dec, 2023

(7 months ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-156) Mar 12, 2018

Drugs and Companies using LEVALBUTEROL TARTRATE ingredient

Market Authorisation Date: 11 March, 2005

Treatment: Treatment or prevention of bronchospasm or asthmatic symptoms

Dosage: AEROSOL, METERED

How can I launch a generic of XOPENEX HFA before it's drug patent expiration?
More Information on Dosage

XOPENEX HFA family patents

Family Patents